KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome.

Joseph Sullivan, Kette Valente, Vicente Villanueva, Adam Strzelczyk, Rima Nabbout, Eiji Nakagawa, Yuehua Zhang, Marta Zolnowska, Yasir Khan, Cheng Dong, Samuel Hsiao, Sarah I Sheikh, Philipp von Rosenstiel, Mahnaz Asgharnejad, Venkatesha Murthy

Epilepsia 67(6) 2796-2807

PMID41784472
PMCIDPMC13285253
DOI10.1002/epi.70164
发表日期2026-03-05
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:CONSORT/入组流程图;FIGURE 3:森林图/亚组分析图;FIGURE 4:生活质量量表图。
摘要

摘要

OBJECTIVE: This study evaluated the efficacy, safety, and tolerability of soticlestat as adjunctive therapy in children and young adults with Dravet syndrome (DS). METHODS: SKYLINE (NCT04940624) was a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial that enrolled patients with DS aged 2-21 years with uncontrolled convulsive seizures (≥4/month despite adequate treatment). Participants received oral soticlestat 300 mg (weight adjusted) or matching placebo twice daily. The total study duration was 16 weeks, comprising 4-week dose titration and 12-week maintenance treatment periods. The primary endpoint was a comparison of monthly convulsive seizure frequency between baseline and the titration/maintenance periods. Key secondary endpoints included several modified Caregiver and Clinical Global Impression of Improvement (GI-I) scales for DS. RESULTS: One hundred forty-four participants were randomized (71 placebo, 73 soticlestat) with a mean (SD) age of 10.3 (5.0) years; 72 (50%) were male, and 117 (81.3%) were receiving ≥3 antiseizure medications. Median change from baseline in convulsive seizure frequency over the full treatment period was -8.64% with placebo (n = 71) and -22.16% with soticlestat (n = 73), a difference of -15.64% (p = .061); in the maintenance treatment period, these changes were -11.99% with placebo and -23.29% with soticlestat, a difference of -14.29% (p = .089). The proportion of participants with ≥50% reduction in convulsive seizures was 9.9% with placebo and 27.4% with soticlestat (nominal p = .008). Soticlestat showed clinically meaningful results in the Caregiver and Clinical GI-I, and Clinical GI-I Seizure Intensity and Duration scales over the 16-week treatment period (all nominal p-values ≤ .004). The most commonly reported treatment-emergent adverse events related to study drug were somnolence, change in seizure presentation, decreased appetite, and insomnia. SIGNIFICANCE: Although statistical significance was narrowly missed, soticlestat showed a numerical benefit over placebo for convulsive seizure decrease. Clinically meaningful benefits across multiple secondary endpoints were observed. No new safety concerns emerged.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Overview of the study design. a Weight‐based dosing in participants weighing <45 kg. SoC, standard of care.
非 KM Figure
FIGURE 2CONSORT (Consolidated Standards of Reporting Trials) flow diagram showing participant enrollment, randomization, allocation, follow‐up, and analysis.
非 KM Figure
FIGURE 3Median change from baseline in convulsive seizure frequency in the modified intent‐to‐treat population. Panels A–C are from the full treatment, maintenance, and full treatment period for the SCN1A+ subgroup. a Hodges–Lehmann approach; p ‐values were computed using a rank analysis of covariance, adjusting for baseline and age stratum. CI, confidence interval; IQR, interquartile range; SCN1A , sodium voltage‐gated channel alpha subunit 1.
非 KM Figure
FIGURE 4Summary of the results from key secondary endpoints. Panels A–E are ≥50% reduction from baseline in convulsive seizure frequency for the full treatment (A) and maintenance period (B), and proportion showing improvement in Care GI‐I (C), CGI‐I (D), and CGI‐I Seizure Intensity and Duration (E) for the full treatment period. Panels F–H are part of the Clinical Global Impression of Improvement (CGI‐I) Non‐Seizure Symptoms measure. Caregiver‐ and clinician‐reported secondary endpoints were assessed at the end of the full treatment period and computed using a cumulative logit model that adjusted for age stratum and used all seven categories of the scale. Improvement is defined as a response of minimally improved, much improved, or very much improved. a Computed using a Cochran–Mantel–Haenszel test stratified by age stratum. b Calculated using a mixed model for repeated measures. CI, confidence interval; Care GI‐I, Caregiver Global Impression of Improvement; LS, least squares; QI‐Disability, Quality of Life Inventory‐Disability.
非 KM Figure